Allenex enter agreement on conditions for loan refinancing

Allenex AB enters agreement for refinancing of existing loans according to the following:

As stated earlier, Allenex and other companies within the group have a bank loan of 30 msek and a convertible 31 msek, due for payment June 30th2013. A refinancing agreement is now ready. The above loans and another bank loan of 27 msek are paid, financed by new loans of 90 msek. The new loans are provided by Allenex main bank Danske Bank to the amount of 70 msek, and by Allenex main owners FastPartner AB and Mohammed Al Amoudi, to the amount of 20 msek. The loans have a term of 3 years and the average interest rate on the new loans (90 million) is currently 5.8%. Refinancing requires the customary written contracts.

For more information please contact:

Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on April 25, 2013, at 08.30 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.


About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See for more information.


Documents & Links